Atossa Therapeutics, Inc. (ATOS)
NASDAQ: ATOS · Real-Time Price · USD
0.8900
+0.0531 (6.34%)
At close: May 13, 2025, 4:00 PM
0.8817
-0.0083 (-0.93%)
Pre-market: May 14, 2025, 6:18 AM EDT
Atossa Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
15
Market Cap
114.96M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ATOS News
- 23 hours ago - Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update - PRNewsWire
- 13 days ago - Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio - GlobeNewsWire
- 14 days ago - Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025 - GlobeNewsWire
- 21 days ago - Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio - GlobeNewsWire
- 4 weeks ago - Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer - PRNewsWire
- 7 weeks ago - Atossa Therapeutics, Inc. (ATOS) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 weeks ago - Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire